cucurbitacin I (JSI-124)

News alerts, weekly reports and conference planners

Company:

H. Lee Moffitt Cancer Center and Research Institute, University of South Florida

Drug class:

JAK2 inhibitor, STAT3 inhibitor

Related drugs:

‹

›

PTPRD mutation	Squamous Cell Carcinoma of Head and Neck	PTPRD mutation	Squamous Cell Carcinoma of Head and Neck	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D
PTPRT promoter methylation	Squamous Cell Carcinoma of Head and Neck	PTPRT promoter methylation	Squamous Cell Carcinoma of Head and Neck	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D

Associations
(2)